EXL 03
Alternative Names: EXL0-03; EXL03Latest Information Update: 03 Nov 2022
At a glance
- Originator Exeliom Biosciences
- Class Antirheumatics
- Mechanism of Action Kynurenine modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Rheumatoid arthritis
Most Recent Events
- 22 Sep 2022 Preclinical trials in Rheumatoid arthritis in France (unspecified route), before September 2022 (Exeliom pipeline, September 2022)